Estrogen Free Polymer Formulations for Food Packaging and Baby Products

用于食品包装和婴儿产品的无雌激素聚合物配方

• 批准号: 7537737
• 负责人: Jacqueline H Laiz
• 金额: $ 13.43万
• 依托单位: PLASTIPURE, INC.
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-06-01 至 2008-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7537737
• 关键词: Adverse effects; Advertising; Aggressive behavior; Antioxidants; Attention; Australia; Behavioral; Biological; Biological Assay; Brain; Canada; Characteristics; Chemicals; China; Client; Cognitive; Condition; Country; Data; Development; Disease; Drug Formulations; Emotions; Endocrine; Environment; Estrogens; Evaluation; Exhibits; Exposure to; Feasibility Studies; Food; Food Additives; Food Container; Food Packaging; Functional disorder; Goals; Government; Grant; Health; Heat Stress Disorders; Heating; Hormones; Human; Individual; Industry; Injection of therapeutic agent; Investigation; Irgafos 168; Irganox 1010; Japan; Learning Disabilities; Legal patent; Letters; Licensing; Life; Mammals; Manufacturer Name; Marketing; Measures; Methods; Molds; Molecular Weight; Motivation; Newborn Infant; One-Step dentin bonding system; Ovarian; Pathology; Persons; Phase; Physiological Processes; Plasticizers; Plastics; Polyethylene; Polyethylenes; Polymers; Polypropylenes; Powder dose form; Prevalence; Procedures; Process; Property; Public Health; Purpose; Reporting; Resistance; Robotics; Sex Orientation; Sister; Small Business Funding Mechanisms; Small Business Innovation Research Grant; Sperm Count Procedure; Testing; Today; Toy; Ultraviolet Rays; Validation; bisphenol A; catalyst; chemical release; child well being; commercialization; consumer product; estrogenic activity; experience; fetal; in vitro Assay; manufacturing process; microwave electromagnetic radiation; monomer; phthalate; phthalates; pressure; social; tinuvin; ultraviolet

DESCRIPTION (provided by applicant): Recent scientific investigations have shown that plastics often leach endocrine disruptor chemicals (EDCs) into the environment. EDCs interfere in various ways with hormones, most commonly estrogens, and can have significant adverse effects on many behavioral and physiological processes such as sperm counts, uterine and ovarian functions, aggressive behaviors, and sexual orientation. ED effects (agonistic or antagonistic) sometimes occur at very low (picomolar to nanomolar) concentrations, especially on fetal or developing mammals (including humans). The prevalence of EDCs in current polymer formulations and their biological effects warrant the development of plastic products free of estrogenic (EA) activity, especially for plastics used to package foodstuffs or to make baby products. In order to meet this need, Plastipure (PPi) is submitting a Phase I SBIR grant to confirm that it is feasible to develop polymer formulations to make plastics that do not release chemicals having EA but that still possess many advantageous characteristics, such as microwavability, resistance to UV light and moisture, similar to current commercially available formulations. PPi proposes to use very sensitive in vitro assays to confirm that plastic products produced from PPi's formulations do not release chemicals having EA before or after exposure to adverse conditions commonly experienced by plastics during normal use (i.e. heat, moisture, UV light). Secondly, PPi plans to identify 3-5 estrogenic free antioxidants that can be utilized in additional formulations to produce EA-free plastics with very diverse physical characteristics. If these Phase I feasibility studies are successful, PPi should have the only known formulations that can make a wide variety of plastic products that do not leach chemicals having EA. These formulations would then be licensed to plastic manufacturers who would then produce EA-free consumer products, such as food containers and baby bottles. Given the increasing concern of individuals for their and their children's well-being and PPi's requests from large and small retail firms, EA-free plastic products should have high commercial potential. PUBLIC HEALTH RELEVANCE: Recent scientific investigations have shown that many chemicals used to manufacture plastics leach into the environment and are endocrine disruptor chemicals (EDCs) that most commonly exhibit estrogenic activity (EA). EDC having EA cause various disorders such as uterine dysfunction or reduced sperm count and abnormal brain maturation leading to pathologies such as learning disabilities, disorders of attention, motivation, emotion, cognitive development, and changes in aggressive behavior and sexual orientation. Given such adverse effects of EDCs having EA on mammals (including humans) there is high scientific, societal, and commercial merit for PPi to confirm that it is feasible to develop EA-free plastic formulations for food packaging and baby products.

描述(申请人提供)：最近的科学研究表明，塑料经常会将内分泌干扰物(EDCs)渗入环境中。EDCs以各种方式干扰激素，最常见的是雌激素，并可对许多行为和生理过程产生显著的不利影响，如精子数量、子宫和卵巢功能、攻击行为和性取向。ED效应(激动性或拮抗性)有时在很低的浓度(皮摩尔到纳摩尔)下发生，特别是在胎儿或发育中的哺乳动物(包括人类)。在目前的聚合物配方中，EDCs的普遍存在及其生物效应要求开发不含雌激素(EA)活性的塑料产品，特别是用于包装食品或制造婴儿产品的塑料。为了满足这一需求，PlattiPure(PPI)正在提交第一阶段SBIR赠款，以确认开发聚合物配方是可行的，以使塑料不释放含有EA的化学品，但仍具有许多有利特性，如微波性、抗紫外线和湿气，类似于当前商业配方。PPI建议使用非常灵敏的体外测试来确认由PPI配方生产的塑料产品在暴露于塑料在正常使用过程中通常经历的不利条件(即热、湿、紫外线)之前或之后不会释放具有EA的化学物质。其次，PPI计划确定3-5种不含雌激素的抗氧化剂，可以在其他配方中使用，以生产具有非常不同物理特性的不含EA的塑料。如果这些第一阶段的可行性研究成功，PPI应该拥有唯一已知的配方，可以生产各种不会浸出含有EA的化学品的塑料产品。然后，这些配方将被授权给塑料制造商，然后这些制造商将生产不含EA的消费品，如食品容器和婴儿奶瓶。鉴于个人日益关注自己和孩子的福祉，以及大小零售公司对PPI的要求，不含EA的塑料产品应该具有很高的商业潜力。与公众健康相关：最近的科学调查表明，许多用于制造塑料的化学品渗入环境，是内分泌干扰物(EDCs)，最常见的是表现出雌激素活性(EA)。EDC进行电针治疗会导致各种疾病，如子宫功能障碍或精子数量减少和大脑发育异常，导致学习障碍、注意力、动机、情绪、认知发展障碍，以及攻击行为和性取向的改变。鉴于EDCs对哺乳动物(包括人类)具有EA的不利影响，PPI具有很高的科学、社会和商业价值，证实开发用于食品包装和婴儿产品的无EA塑料配方是可行的。